Reducing Risk of Dementia Through Deprescribing — R2D2  

Dementia Clinical Trial

Official title: Reducing Risk of Dementia Through Deprescribing (R2D2)

Status Recruiting

Clinical Trial Summary

A cluster-randomized controlled trial (RCT) called "Reducing Risk of Dementia through Deprescribing" (R2D2) to evaluate the impact of a deprescribing intervention on important cognitive and safety outcomes.

Clinical Trial Description

The R2D2 study will test whether the adverse cognitive effects of anticholinergic medications are reversible by implementing a pharmacist-based deprescribing intervention for older adults within primary care practices. Two groups will be recruited: providers (physicians and advanced practice providers including nurse practitioners), and patients. Primary care providers of those prescribed eligible anticholinergic medications will be recruited for participation in the study, and their patients who also meet eligible criteria will be subsequently approached and recruited. Participants will be randomized to one of two groups: the deprescribing intervention group or usual care; the intervention group will receive a pharmacist-based deprescribing intervention, while the usual care group will receive care as usually provided by their primary and/or specialty care providers. The intervention and follow-up data collection will occur over 24 months in order to test the long-term impact of the intervention on the planned clinical outcomes. Study outcomes include cognition (primary) and safety (secondary) through validated self-reported scales. ;

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer Disease, Late Onset
• Dementia

• NCT number: NCT04270474
• Study type: Interventional
• Source: Indiana University
• Contact: Noll L Campbell, PharmD, MS
• Phone: (317)274-9051
• Email: campbenl@iu.edu
• Status: Recruiting
• Phase: N/A
• Start date: July 20, 2020
• Completion date: June 30, 2026